Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 28, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Dec 10, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...
-
Nov 1, 2007-- First quarter revenue increased $43 million, or 12 percent, to $383 million
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...
-
Nov 1, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has...
-
Oct 31, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors appointed President and Chief Executive Officer, Joseph C. Papa, to be Chairman of its Board of Directors....
-
Oct 30, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on December 18, 2007 to shareholders of record on...
-
Oct 19, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2008 on Thursday, November 1, 2007 at approximately 8:00 a.m. (ET)....
-
Sep 27, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of...
-
Sep 19, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution,...
-
Sep 14, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that President and CEO, Joseph C. Papa and the Perrigo management team will provide a review of the Company business for the financial...
-
Sep 13, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Mori Arkin, Vice Chairman and General Manager, Perrigo Global Generics and API, has advised the Company that he will retire at the...
-
Aug 23, 2007* Full year revenue increased 6 percent to $1.45 billion; earnings per share increased 4 percent to $0.79, and rose 7 percent to $0.89 on a non-GAAP basis
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for fiscal year 2007 and the fourth quarter ended June 30, 2007. Perrigo Company (in thousands, except per share amounts) Fourth...
-
Aug 16, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on September 18, 2007 to shareholders of...
-
Aug 9, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2007 on Thursday, August 23, 2007 at approximately 8:00 a.m. (ET). The Company...
-
Jul 11, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed its transaction to acquire Qualis, Inc., a privately-owned manufacturer of store brand pediculicide products for...
-
Jun 20, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval to Dexcel Pharma Technologies, Ltd. (Dexcel) for its...
-
Jun 7, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's President and CEO will present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference on...
-
Jun 6, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that a federal court has ruled in its favor in patent litigation involving Famotidine Complete. Perrigo had been sued by Johnson &...
-
May 30, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...
-
May 8, 2007Third Quarter Sales $362 million, up 9%
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the third quarter of fiscal year 2007 ended March 31, 2007. Perrigo Company (in thousands, except per share amounts)...
-
May 2, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on June 19, 2007 to shareholders of record on...
-
May 1, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May...
-
Apr 27, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2007 on Tuesday, May 8, 2007 at approximately 8:00 a.m. (ET). The...
-
Apr 5, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the CIBC World Markets Biotechnology & Pharmaceuticals Conference on...
-
Mar 27, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced an organizational restructuring to further enhance the management of the Company's global operations. John Hendrickson has been named...